Protirelin
As of the edition of 20 October 2026, Protirelin is a protein: marketed, first approved in 1982 (US); acts on TRHR; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Protein
- Brand name
- Thypinone
- First approved
- 1 January 1982 (US)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- FERRING (FRANCE); 3 holders in all
- Registered trials
- 6, 2 stopped early
- Disease areas
- Hormones; Cancer; Inherited and neonatal; Lungs and airways; Nervous system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TRHR | Thyrotropin-releasing hormone receptor | P34981 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 2 | 0 | 0 |
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 2 | 1 | 0 | 1 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 6 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Abbott | Acquired holder and Earlier holder | 2003 to now |
| Ferring Pharmaceuticals | Acquired holder | 2003 to now |
| Sanofi | Later holder |